Cryo Cell International (CCEL) Share-based Compensation (2010 - 2026)

Cryo Cell International has disclosed Share-based Compensation across 17 years of filings, most recently posting $158549.0 for Q1 2026.

• In Q1 2026, Share-based Compensation fell 46.62% year-over-year to $158549.0; the TTM figure through Feb 2026 stood at $278131.0 (down 63.9% YoY), while the FY2025 annual figure was $417000.0, down 46.61% from the prior year.
• Share-based Compensation rose to $158549.0 in Q1 2026, from $42802.0 in the prior quarter.
• Over the last five years, Share-based Compensation for CCEL reached as high as $313000.0 in Q1 2023 and fell as low as $31896.0 in Q1 2022.
• The 5-year median for Share-based Compensation is $157000.0 (2023), against an average of $154957.9.
• Annual changes were most pronounced in 2023 — Share-based Compensation jumped 881.31% — and 2025, when it plunged 77.53%.
• A 5-year view of Share-based Compensation shows it stood at $150904.0 in 2022, then increased by 16.17% to $175310.0 in 2023, then retreated by 14.69% to $149565.0 in 2024, then sank by 71.38% to $42802.0 in 2025, then soared by 270.42% to $158549.0 in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $158549.0, $42802.0, and $36780.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.